Purpose: To evaluate the intraocular pressure (IOP)-lowering effect and saf
ety of latanoprost, a prostaglandin analogue, in patients with primary open
-angle glaucoma or ocular hypertension.
Method: One hundred and twenty-four Japanese patients with primary open-ang
le glaucoma or ocular hypertension were enrolled in this open-labeled study
and were treated with 0.005% latanoprost once daily for 1 year.
Results: At all follow-up visits there was a significant (P < .001) reducti
on in IOP compared with the baseline value. After 1 year, the IOP was reduc
ed by 5.4 +/- 2.9 (mean +/- SD) mm Hg from a baseline value of 23.5) 2.2 mm
Hg. No evidence of an upward drift in the IOP was observed during the trea
tment period. The most frequently reported adverse ocular events were mild
conjunctival hyperemia and iris pigmentation. Very few adverse systemic eve
nts were observed.
Conclusions: Latanoprost eye drops showed a marked and stable IOP-lowering
effect during the 1-year treatment period. Furthermore, latanoprost was wel
l-tolerated and should be a valuable contribution to the management of glau
coma. (C) 2000 Japanese Ophthalmological Society.